FDA approved BridgeBio Pharma's Attruby for treating transthyretin amyloid cardiomyopathy in adults, aiming to reduce cardiovascular deaths. The approval led to a $500m payment under a royalty funding agreement. The Phase III trial showed positive results, prompting plans for global approvals.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing